Posted on 11/17/17
Evelo Biosciences and Mayo Clinic Collaborate
Evelo Biosciences, a biotechnology company pioneering the therapeutic modality of monoclonal microbials, today announced a collaboration with Mayo Clinic to develop and commercialize monoclonal microbials for . . .
Posted on 11/16/17
Arsanis Announces Pricing of Initial Public Offering
WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious . . .
Posted on 11/15/17
Leap Therapeutics Announces $18 Million Private Placement Offering
CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into . . .
Posted on 11/15/17
Cognex Delivers on Its Monster Quarter
Machine vision leader Cognex Corporation (NASDAQ:CGNX) set the bar high with last quarter's financial release when the company reported record results and forecast a "monster quarter." . . .
Posted on 11/15/17
Keryx Biopharma Down 17% Despite Drug Approval
Last week, Keryx Biopharmaceuticals (NASDAQ:KERX) fell a whopping 17% after missing analyst estimates for its key drug, Auryxia, which is used to control phosphorus levels in . . .
Posted on 11/14/17
Albireo Reports Third Quarter 2017 Financial Results
BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its . . .
Posted on 11/14/17
Your Daily Pharma Scoop: Regeneron's Appeal, Good News For Amgen, Bristol-Myers' Sprycel
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace.Analysis of . . .
Posted on 11/14/17
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 5,600,000 shares of . . .
Posted on 11/13/17
RXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics, and Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today . . .
Posted on 11/13/17
Alnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of shares of its common stock . . .
Posted on 11/13/17
SCIEX Announces Joint Venture With Zhenjang Dian Diagnostics in China
FRAMINGHAM, Mass. & SHANGHAI--(BUSINESS WIRE)--SCIEX Diagnostics, the in vitro diagnostics (IVD) division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced . . .
Posted on 11/13/17
Rodin Therapeutics Announces Award of Grant Support From The Michael J. Fox Foundation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rodin Therapeutics, a biotechnology company discovering and developing novel therapeutics to boost synaptic connections and resilience, today announced that it has received funding support . . .
Posted on 11/13/17
Sage Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has . . .
Posted on 11/13/17
Spero Therapeutics Announces Underwriters’ Option Exercise
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for . . .
Posted on 11/13/17
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ:ACAD) or Biogen(NASDAQ:BIIB) stock.So far . . .
Posted on 11/13/17
Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced its inclusion . . .
Posted on 11/12/17
Voyager Therapeutics Closes Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, . . .
Posted on 11/9/17
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
CANTON, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2017 and provided a . . .
Posted on 11/9/17
CVS Health Joins with the National Consortium of State-Operated Comprehensive Rehabilitation Centers
CVS Health [NYSE: CVS] today announced a collaboration with the National Consortium of State-Operated Comprehensive Rehabilitation Centers (NCSOCRC) to help Americans with disabilities find meaningful employment . . .
Posted on 11/8/17
Exonics Therapeutics Raises $40 Million in Series A Financing
Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne muscular dystrophy
Posted on 11/8/17
Merrimack Reports Third Quarter 2017 Financial Results
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its third quarter 2017 financial results for the period ended September 30, 2017."The third quarter marked continued execution on . . .
Posted on 11/8/17
ArQule Announces $9.5 Million Private Placement of Preferred Stock
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with institutional investors led by The Pontifax Group pursuant to which the . . .
Posted on 11/8/17
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
What happenedShares of ImmunoGen (NASDAQ:IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according . . .
Posted on 11/8/17
Seres Therapeutics Awarded Grant from CARB-X
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator) to support continued preclinical research . . .
Posted on 11/8/17
Sponsor and Exhibitor Opportunities Announced for 2018 Emerging Trends in Wellness Conference
Make strategic business connections in human resources, employee benefits, insurance, wellness, health and nutrition Wellness Workdays, a leading provider of corporate wellness programs, announces sponsor and . . .
Boston
